Key facts
- It has raised $28.1M; the latest was Early Stage VC ($14.1M) in Dec 2025.
- Notable investors include Lapam Capital, HaiBang Ventures, Hangzhou Betta Investment, Hangzhou Haibang Fenghua Investment Management, Zhejiang Jinkong Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for SynRx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for SynRx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynRx Therapeutics
Developer of innovative drugs designed for DNA damage repair (DDR). The company focuses on the development of novel anti-tumor drugs using synthetic lethality approaches, providing medical industry users with effective oncology solutions.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Website
- synrx.cn/
- Ownership
- Privately Held (backing)
SynRx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynRx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynRx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.